Evolent Health, Inc. (EVH) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $3.02 (-4.56%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Sean Dodge | BMO Capital | $3.50 | +15.9% |
| Feb 2, 2026 | David Larsen | BTIG | $10.00 | +231.0% |
| Jan 16, 2025 | Kevin Caliendo | UBS | $14.00 | +363.4% |
| Jan 15, 2025 | Jailendra Singh | Truist Financial | $20.00 | +562.0% |
| Jan 14, 2025 | Sean Dodge | RBC Capital | $17.00 | +462.7% |
| Jan 10, 2025 | Constantine Davides | JMP Securities | $18.00 | +495.8% |
| Nov 18, 2024 | Mohan Naidu | Oppenheimer | $28.00 | +826.8% |
| Oct 17, 2024 | Jeff Garro | Stephens | $38.00 | +1157.9% |
| Aug 9, 2024 | Jailendra Singh | Truist Financial | $33.00 | +992.4% |
| Jun 5, 2024 | Sean Dodge | RBC Capital | $42.00 | +1290.3% |
| May 14, 2024 | Jailendra Singh | Truist Financial | $28.00 | +826.8% |
| Apr 17, 2024 | Jessica Tassan | Piper Sandler | $51.00 | +1588.2% |
| Mar 28, 2024 | Richard Close | Canaccord Genuity | $44.00 | +1356.5% |
Top Analysts Covering EVH
EVH vs Sector & Market
| Metric | EVH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.19 | 2.25 | 2.42 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +127.7% | +16316.0% | +17.1% |
| P/E Ratio | -0.77 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.45B | $2.49B | $2.53B | 12 |
| 2027-12-31 | $2.63B | $2.88B | $3.17B | 12 |
| 2028-03-31 | $609M | $647M | $677M | 4 |
| 2028-06-30 | $741M | $788M | $823M | 6 |
| 2028-09-30 | $777M | $826M | $863M | 9 |
| 2028-12-31 | $812M | $863M | $903M | 4 |
| 2029-03-31 | $821M | $873M | $913M | 6 |
| 2029-06-30 | $846M | $900M | $941M | 8 |
| 2029-09-30 | $872M | $927M | $969M | 5 |
| 2029-12-31 | $892M | $948M | $992M | 5 |
| 2030-12-31 | $4.17B | $4.40B | $4.71B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.09 | $0.14 | $0.16 | 7 |
| 2027-12-31 | $0.37 | $0.42 | $0.46 | 7 |
| 2028-03-31 | $0.05 | $0.05 | $0.06 | 2 |
| 2028-06-30 | $0.11 | $0.11 | $0.12 | 2 |
| 2028-09-30 | $0.12 | $0.13 | $0.14 | 2 |
| 2028-12-31 | $0.13 | $0.14 | $0.15 | 2 |
| 2029-03-31 | $0.14 | $0.15 | $0.16 | 1 |
| 2029-06-30 | $0.20 | $0.22 | $0.23 | 1 |
| 2029-09-30 | $0.22 | $0.24 | $0.25 | 1 |
| 2029-12-31 | $0.20 | $0.22 | $0.23 | 1 |
| 2030-12-31 | $1.01 | $1.08 | $1.18 | 2 |
Frequently Asked Questions
What is the analyst consensus for EVH?
The consensus among 16 analysts covering Evolent Health, Inc. (EVH) is Buy with an average price target of $6.30.
What is the highest price target for EVH?
The highest price target for EVH is $51.00, set by Jessica Tassan at Piper Sandler on 2024-04-17.
What is the lowest price target for EVH?
The lowest price target for EVH is $3.50, set by Sean Dodge at BMO Capital on 2026-02-25.
How many analysts cover EVH?
16 analysts have issued ratings for Evolent Health, Inc. in the past 12 months.
Is EVH a buy or sell right now?
Based on 16 analyst ratings, EVH has a consensus rating of Buy (2.19/5) with a +127.7% upside to the consensus target of $6.30.
What are the earnings estimates for EVH?
Analysts estimate EVH will report EPS of $0.14 for the period ending 2026-12-31, with revenue estimated at $2.49B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.